Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.3 (
phospholipase C
)
18,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Our previous studies have shown that both increase in Ca2+ levels and activation of protein kinase C (PKC) are required for monocyte-mediated O2- production and low density lipoprotein (LDL) peroxidation. Phosphoinositide-specific
phospholipase C
(phosphoinositidase C or
PIC
) is believed to mediate release of intracellular Ca2+ through InsP3 formation and activation of PKC through diacylglycerol (DAG). In these studies, we investigated the
PIC
pathway for its participation in monocytic cell-mediated lipid peroxidation of LDL. We found substantial InsP3 formation in opsonized zymosan (ZOP)-activated U937-b cells, indicating the activation of
PIC
. Both inhibition of
PIC
by the
PIC
inhibitor U-73122 and reduction of the supply of the precursor lipid by lithium chloride suppressed InsP3 formation but did not alter LDL lipid peroxidation nor O2- production by activated cells. Furthermore, we also found that suppression of
PIC
activity had no substantial inhibitory effect on PKC activity in ZOP-activated human monocytes. Our data suggest that
PIC
activity is induced upon cell activation resulting in increased levels of InsP3. The activity of this pathway, however, is not required for cell-mediated O2- production, PKC activation or LDL oxidation.
...
PMID:Activation of PKC, superoxide anion production and LDL lipid peroxidation are not dependent on phosphoinositide-specific phospholipase C activity in U937 cells. 952 26
